LakeShore Biopharma Co., Ltd. (LSB)
(Delayed Data from NSDQ)
$2.00 USD
-0.30 (-12.96%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $2.00 0.00 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.00 USD
-0.30 (-12.96%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $2.00 0.00 (-0.10%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 41.30% and 5.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -8.11% and 53.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 14.29% and 72.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?